Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Cell 131, 861872
doi: 10.1080/13543784.2025.2473062, 22
The glucagon arm is what sets it apart from anything else clinically available
List JF, He H, Habener JF
Inadequate use of newer treatments and glycemic control by cardiovascular risk and sociodemographic groups in US adults with diabetes in the NIH Precision Medicine Initiative All of Us Research Program
Quick Take & Core Data: Average body weight reduction: 30.3% at 104 weeks [1] Dose cohort outcome: 45% of patients in the 12 mg group lost 30% or more body weight [1] Diabetic weight loss efficacy: 16.8% reduction over 40 weeks [2] Retatrutide is a triple agonist that binds directly to three metabolic pathways [1, 3]
US$ 28.72
US$ 26.48
US$ 29.96
